AZN
HealthcareAstraZeneca PLC
$91.22
$-0.35 (-0.38%)
Jan 5, 2026
Price History (1Y)
Analysis
AstraZeneca PLC is a multinational healthcare company that operates within the sector of Healthcare and the industry of Drug Manufacturers - General. With a market capitalization of $282.83 billion, it is one of the largest companies in its sector, employing approximately 94,300 individuals worldwide. From a financial perspective, AstraZeneca demonstrates strong profitability metrics, with gross margins standing at 83.3%, operating margins at 24.1%, and profit margins at 16.2%. The company generates significant returns on equity (ROE) of 21.7% and assets (ROA) of 9.1%. However, its debt-to-equity ratio is substantial at 71.05, indicating a relatively high level of indebtedness. AstraZeneca's balance sheet also shows cash reserves of $8.18 billion and outstanding debt of $32.66 billion. In terms of valuation context, AstraZeneca's price-to-earnings (P/E) ratio stands at 30.41 on a trailing twelve-month (TTM) basis, while its forward P/E is 17.71. The company has achieved revenue growth of 12.0% year-over-year and earnings growth of 78.0%, contributing to its relatively high dividend yield of 171.0%. AstraZeneca's payout ratio is 52.0%, indicating a significant portion of earnings are distributed as dividends.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Visit website →Key Statistics
- Market Cap
- $282.83B
- P/E Ratio
- 30.41
- 52-Week High
- $94.02
- 52-Week Low
- $61.24
- Avg Volume
- 5.07M
- Beta
- 0.19
- Dividend Yield
- 171.00%
Company Info
- Industry
- Drug Manufacturers - General
- Exchange
- NMS
- Country
- United Kingdom
- Employees
- 94,300